Clinical Trial Update: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 inpatient trial assessing PF-02545920 for acute exacerbation of schizophrenia; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PF-02545920

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2018-03-20